List view / Grid view
In this article, experts from Charles River Associates discuss how the introduction of cell and gene therapies will impact upon various aspects of the healthcare system, from provision of care to delivery and supply, and pricing and market access.
Plasma-derived therapies and medicines provide life-changing treatments for patients around the world who suffer from serious, and often rare, diseases that affect the immune system or result from non-functioning proteins in blood plasma. Carole Resman, Executive Vice President Production at LFB, describes the complex and highly regulated manufacturing process of…
The occurrence of non-fatal thrombotic events in Phase III study participants has called into question the safety of concizumab.
Sanofi and Bioverativ Inc., have entered into a definitive agreement under which Sanofi will acquire all of the outstanding shares of Bioverativ...
Researchers have found that polymer and hybrid silica-coated microcapsules are efficient in genome-editing...
We caught up with Naghmana Bajwa, MD, Global Medical Affairs Haematology Lead at Shire to find out the latest in haemophilia disease research...
20 June 2016 | By Victoria White, Digital Content Producer
Freeline is developing and commercialising gene therapies for bleeding and other life threatening or debilitating disorders...
13 May 2016 | By Victoria White, Digital Content Producer
The European Commission has approved Alprolix (rFIXFc) for the treatment of haemophilia B and maintained its orphan designation...
3 May 2016 | By Victoria White, Digital Content Producer
The new company, to be named at a later date, will focus on the discovery and development of therapies for the treatment of haemophilia...
23 March 2016 | By Victoria White
CSL Behring’s Idelvion and Sobi/Biogen’s Alprolix will compete intensely for a share of the haemophilia B market following their expected European approvals...
